{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:51:01Z","timestamp":1794559861096,"version":"4.9.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"The National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cochrane Infrastructure"},{"name":"Cochrane Pain"},{"name":"Palliative and Supportive Care Review Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To summarize and evaluate Cochrane reviews of pharmacological therapies for adults with fibromyalgia syndrome (FMS) pain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Systematic search of Cochrane Database of Systematic Reviews to May 2024. Generic quality assessment used AMSTAR-2 criteria, validity checks of potentially critical factors in evaluation of analgesic efficacy and assessment of susceptibility of results to publication bias. Pain outcomes were participant-reported pain relief of \u226530% or \u226550%, or PGIC much or very much improved.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-one reviews (87 trials, 17\u2009631 patients) were included. All rated moderate (15) or high-quality (6) using AMSTAR-2 and at least seven of eight critical pain criteria were met by 13 of 21 reviews. Diagnosis of FMS used recognized criteria. Seven reviews found no trials (carbamazepine, clonazepam, lamotrigine, phenytoin, oxycodone, topiramate or valproate), seven had limited and inadequate data (antipsychotics, cannabinoids, combination therapy, gabapentin, lacosamide, monoamine oxidase inhibitors, NSAIDs) and two were subject to publication bias (amitriptyline, SSRI). Mirtazapine had moderate evidence of no effect. Duloxetine, milnacipran and pregabalin had moderate\/good evidence of substantial pain relief for 4\u201312\u2009weeks in around 1 in 10 adults with moderate or severe FMS pain, without evidence of efficacy beyond six months. Serious adverse events were no more common than with placebo. There was no evidence about who might benefit or experience adverse events. There was no substantial efficacy evidence for other medicines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Duloxetine, milnacipran and pregabalin had good evidence that about 1 person in 10 with moderate or severe pain experienced pain intensity reduction by at least 50%.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae707","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T18:06:59Z","timestamp":1734718019000},"page":"2385-2394","source":"Crossref","is-referenced-by-count":27,"title":["Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews"],"prefix":"10.1093","volume":"64","author":[{"given":"Andrew","family":"Moore","sequence":"first","affiliation":[{"name":"Newton Ferrers , Plymouth,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bidonde","sequence":"additional","affiliation":[{"name":"School of Rehabilitation Science, University of Saskatchewan , Saskatoon, SK,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Fisher","sequence":"additional","affiliation":[{"name":"Centre for Pain Research, University of Bath , Bath,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen , M\u00fcnchen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae Frances","family":"Bell","sequence":"additional","affiliation":[{"name":"Regional Centre of Excellence in Palliative Care, Haukeland University Hospital , Bergen,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Perrot","sequence":"additional","affiliation":[{"name":"Centre de la Douleur, H\u00f4pital Cochin, Universit\u00e9 Paris Cit\u00e9, INSERM U987, H\u00f4pital Cochin , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzi","family":"Makri","sequence":"additional","affiliation":[{"name":"Cyprus League of People with Rheumatism , Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Straube","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Department of Medicine, University of Alberta , Edmonton, AB,","place":["Canada"]},{"name":"School of Public Health, University of Alberta , Edmonton, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025050316122185500_keae707-B1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain\u2014establishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"key":"2025050316122185500_keae707-B2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.33360","article-title":"Development of responder definitions for fibromyalgia clinical trials","volume":"64","author":"Arnold","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025050316122185500_keae707-B3","doi-asserted-by":"crossref","first-page":"152248","DOI":"10.1016\/j.semarthrit.2023.152248","article-title":"Effectiveness of non-pharmacological interventions for fibromyalgia and quality of review methods: an overview of Cochrane Reviews","volume":"63","author":"Bidonde","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316122185500_keae707-B4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2025050316122185500_keae707-B5","author":"World Health Organization"},{"key":"2025050316122185500_keae707-B6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/j.pain.0000000000001390","article-title":"The IASP classification of chronic pain for ICD-11: chronic primary pain","volume":"160","author":"Nicholas","year":"2019","journal-title":"Pain"},{"key":"2025050316122185500_keae707-B7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","article-title":"Worldwide epidemiology of fibromyalgia","volume":"17","author":"Queiroz","year":"2013","journal-title":"Curr Pain Headache Rep"},{"key":"2025050316122185500_keae707-B8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/ejp.1252","article-title":"Comorbid fibromyalgia: a qualitative review of prevalence and importance","volume":"22","author":"Fitzcharles","year":"2018","journal-title":"Eur J Pain"},{"key":"2025050316122185500_keae707-B9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR revised recommendations for the management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025050316122185500_keae707-B10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00482-017-0201-6","article-title":"General principles and coordination of care and patient education in fibromyalgia syndrome. Updated guideline 2017 and review of systematic reviews","volume":"31","author":"Petzke","year":"2017","journal-title":"Schmerz"},{"key":"2025050316122185500_keae707-B11","first-page":"CD011279","article-title":"Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews","volume":"4","author":"Geneen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B12","first-page":"CD007407","article-title":"Psychological therapies for the management of chronic pain (excluding headache) in adults","volume":"8","author":"Williams","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B13","first-page":"CD010292","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome","volume":"1","author":"H\u00e4user","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B14","first-page":"CD007115","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","volume":"2014","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B15","first-page":"CD008242","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","volume":"2015","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B16","first-page":"CD012188","article-title":"Gabapentin for fibromyalgia pain in adults","volume":"1","author":"Cooper","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B17","first-page":"CD007076","article-title":"Pregabalin for acute and chronic pain in adults","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B18","first-page":"CD010782","article-title":"Anticonvulsants for fibromyalgia","volume":"10","author":"Uceyler","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B19","first-page":"CD010567","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia\u2014an overview of Cochrane reviews","volume":"11","author":"Wiffen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"key":"2025050316122185500_keae707-B21","doi-asserted-by":"crossref","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ"},{"key":"2025050316122185500_keae707-B22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"key":"2025050316122185500_keae707-B23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Andrew","year":"2014","journal-title":"Pain Practice"},{"key":"2025050316122185500_keae707-B24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1471-2474-12-125","article-title":"Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response","volume":"12","author":"Straube","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"2025050316122185500_keae707-B25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/rheumatology\/keu332","article-title":"Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies","volume":"54","author":"Conaghan","year":"2015","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025050316122185500_keae707-B26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.sjpain.2016.07.002","article-title":"Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial","volume":"13","author":"Peloso","year":"2016","journal-title":"Scand J Pain"},{"key":"2025050316122185500_keae707-B27","first-page":"CD013151","article-title":"Pharmacological therapies for fibromyalgia (fibromyalgia syndrome) in adults\u2014an overview of Cochrane Reviews","volume":"2021","author":"Moore","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"2025050316122185500_keae707-B28","doi-asserted-by":"crossref","first-page":"e070849","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"key":"2025050316122185500_keae707-B29","first-page":"485","volume-title":"Textbook of rheumatology","author":"Smythe","year":"1981","edition":"7th edn"},{"key":"2025050316122185500_keae707-B30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3899\/jrheum.100594","article-title":"Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia","volume":"38","author":"Wolfe","year":"2011","journal-title":"J Rheumatol"},{"key":"2025050316122185500_keae707-B31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025050316122185500_keae707-B32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316122185500_keae707-B33","first-page":"21","article-title":"Primary fibromyalgia syndrome: current concepts","volume":"10","author":"Yunus","year":"1984","journal-title":"Compr Ther"},{"key":"2025050316122185500_keae707-B34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0049-0172(81)90096-2","article-title":"Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls","volume":"11","author":"Yunus","year":"1981","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316122185500_keae707-B35","first-page":"115","article-title":"Primary fibromyalgia","volume":"25","author":"Yunus","year":"1982","journal-title":"Am Fam Physician"},{"key":"2025050316122185500_keae707-B36","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"2025050316122185500_keae707-B37","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/j.pain.0000000000001941","article-title":"Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews","volume":"162","author":"Moore","year":"2021","journal-title":"Pain"},{"key":"2025050316122185500_keae707-B38","first-page":"15","volume-title":"Systematic reviews in pain research: methodology refined","author":"Moore","year":"2008"},{"key":"2025050316122185500_keae707-B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol Assess"},{"key":"2025050316122185500_keae707-B40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"2025050316122185500_keae707-B41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything\u2014large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"key":"2025050316122185500_keae707-B42","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/bmj.296.6632.1313","article-title":"Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates","volume":"296","author":"Morris","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2025050316122185500_keae707-B43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"key":"2025050316122185500_keae707-B44","author":"Cochrane Effective Practice and Organisation of Care Group","year":"2017"},{"key":"2025050316122185500_keae707-B45","first-page":"CD008659","article-title":"Single dose oral analgesics for acute postoperative pain in adults\u2014an overview of Cochrane reviews","volume":"2015","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B46","first-page":"CD012592","article-title":"Opioids for cancer pain\u2014an overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B47","first-page":"CD008244","article-title":"Milnacipran for pain in fibromyalgia in adults","volume":"2015","author":"Cording","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B48","first-page":"CD009486","article-title":"Clonazepam for neuropathic pain and fibromyalgia in adults","volume":"2012","author":"Corrigan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B49","first-page":"CD011824","article-title":"Amitriptyline for fibromyalgia in adults","volume":"5","author":"Moore","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B50","first-page":"CD009807","article-title":"Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome","volume":"4","author":"Tort","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B51","first-page":"CD011735","article-title":"Selective serotonin reuptake inhibitors for fibromyalgia syndrome","volume":"2015","author":"Walitt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B52","first-page":"CD012708","article-title":"Mirtazapine for fibromyalgia in adults","volume":"8","author":"Welsch","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B53","first-page":"CD010292","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia","volume":"2","author":"Welsch","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B54","first-page":"CD009485","article-title":"Phenytoin for neuropathic pain and fibromyalgia in adults","volume":"2012","author":"Birse","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B55","first-page":"CD011790","article-title":"Pregabalin for pain in fibromyalgia in adults","volume":"9","author":"Derry","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B56","first-page":"CD009183","article-title":"Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults","volume":"2011","author":"Gill","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B57","first-page":"CD009318","article-title":"Lacosamide for neuropathic pain and fibromyalgia in adults","volume":"2012","author":"Hearn","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B58","first-page":"CD008314","article-title":"Topiramate for neuropathic pain and fibromyalgia in adults","volume":"2013","author":"Wiffen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B59","first-page":"CD006044","article-title":"Lamotrigine for chronic neuropathic pain and fibromyalgia in adults","volume":"2013","author":"Wiffen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B60","first-page":"CD005451","article-title":"Carbamazepine for chronic neuropathic pain and fibromyalgia in adults","volume":"2014","author":"Wiffen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B61","first-page":"CD011804","article-title":"Antipsychotics for fibromyalgia in adults","volume":"2016","author":"Walitt","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B62","first-page":"CD011694","article-title":"Cannabinoids for fibromyalgia","volume":"7","author":"Walitt","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B63","first-page":"CD012329","article-title":"Oxycodone for pain in fibromyalgia in adults","volume":"9","author":"Gaskell","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B64","first-page":"CD012332","article-title":"Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults","volume":"3","author":"Derry","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B65","first-page":"CD010585","article-title":"Combination pharmacotherapy for the treatment of fibromyalgia in adults","volume":"2","author":"Thorpe","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025050316122185500_keae707-B66","author":"European Commission","year":"2018"},{"key":"2025050316122185500_keae707-B67","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bja.2022.09.030","article-title":"Flawed, futile, and fabricated\u2014features that limit confidence in clinical research in pain and anaesthesia: a narrative review","volume":"130","author":"Moore","year":"2023","journal-title":"Br J Anaesth"},{"key":"2025050316122185500_keae707-B68","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s42358-020-00137-5","article-title":"Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews","volume":"60","author":"de Farias","year":"2020","journal-title":"Adv Rheumatol"},{"key":"2025050316122185500_keae707-B69","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00482-017-0207-0","article-title":"Drug therapy of fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles","volume":"31","author":"Sommer","year":"2017","journal-title":"Schmerz"},{"key":"2025050316122185500_keae707-B70","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2474-11-150","article-title":"Pregabalin in fibromyalgia\u2014responder analysis from individual patient data","volume":"11","author":"Straube","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"2025050316122185500_keae707-B71","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/03007995.2019.1629757","article-title":"Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study","volume":"35","author":"Arnold","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2025050316122185500_keae707-B72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/918216","article-title":"2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary","volume":"18","author":"Fitzcharles","year":"2013","journal-title":"Pain Res Manag"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae707\/61249415\/keae707.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2385\/61249415\/keae707.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2385\/61249415\/keae707.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:12:41Z","timestamp":1746303161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2385\/7929825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":72,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,20]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae707","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,20]]}}}